United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $4.09, $1.07 better than the analyst estimate of $3.02. Revenue for the quarter came in at $446.5 million versus the consensus estimate of $378.75 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.